videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

SynAct Pharma

Language: en Moderator: Lars Frick Venue: Helio GT 30, Grev Turegatan 30 Stockholm Sector: Health care - Pharmaceuticals & Biotechnology Activity: Capital Markets DaySynAct Pharma AB (“SynAct...

<div>Language: en 
Moderator: Lars Frick 
Venue: Helio GT 30, Grev Turegatan 30 Stockholm 
Sector: Health care - Pharmaceuticals &amp; Biotechnology 
Activity: Capital Markets Day<div>SynAct Pharma AB (&#x201c;SynAct&#x201d;) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day on Monday, September 23, 10:00-13:00 CEST at GT30, Grev Turegatan 30 in Stockholm.

The presentations will give an update on SynAct Pharma&#x2019;s strategy and offer an opportunity for participants to learn more about resomelagon&#x2019;s role in resolving inflammation through selective activation of the melanocortin system and the company&#x2019;s next clinical development of resomelagon with the Phase IIb clinical study ADVANCE in the US and Europe.

Agenda

10:00 Introduction and corporate update &#x2013; Jeppe &#xd8;vlesen, CEO 
10:15 SynAct strategy and direction &#x2013; Anders Kronborg, Chairman of the Board 
10:25 Resolution therapy &#x2013; Novel approach to the clinical management of inflammatory diseases &#x2013; Prof. Mauro Perretti 
10:45 Current and Future Treatments of Early Rheumatoid Arthritis and the Medical Need &#x2013; Asger Reinstrup Bihlet, CSO at Sanos Group 
11:05 Q&amp;A session 
11:25&#xa0;Break 
11:40 Resomelagon program and ADVANCE study &#x2013; Thomas Jonassen, CSO 
12:05 Emerging Clinical profile in newly-diagnosed RA patients &#x2013; the business case &#x2013; Jim Knight, CBO 
12:30 Sector and market overview &#x2013; Sten Scheibye, Member of the Board 
12:40 Q&amp;A session 
12:55 Wrap-up and summary &#x2013; Jeppe &#xd8;vlesen, CEO 
13:00 Reception and lunch

The Capital Markets Day will be held in English. Presentation material will be available on SynAct&#x2019;s website afterwards.

Registration for the Capital Markets Day is made by emailing&#xa0;<a href="mailto:investor.relations@synactpharma.com">investor.relations@synactpharma.com</a>

The last day to register is September 19, 2024.

A recorded version of the event will be published afterwards.

&#xa0;
</div></div>

SynAct Pharma, Capital Markets Day, 2024

Recent videos